INMB
INMB clinical trials: Inmune Bio, Inc.
Every trial on ClinicalTrials.gov where Inmune Bio, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 7
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
INMB on the catalyst calendar · INMB registry changes
- Primary completion May 12, 2025ActualPhase 2NCT05318976A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationInmune Bio, Inc. · Alzheimer DiseaseCompletedINMBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2021ActualPhase 2/Phase 3NCT04370236INB03 for the Treatment of Pulmonary Complications From COVID-19Inmune Bio, Inc. · COVID-19TerminatedINMBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 28, 2024ActualPhase 1NCT05933070A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AMLInmune Bio, Inc. · CancerTerminatedINMBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 10, 2025ActualPhase 1/Phase 2NCT06056791Study of INKmune in Patients With mCRPC (CaRe Prostate)Inmune Bio, Inc. · CancerCompletedINMBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 5, 2024ActualPhase 2NCT05522387An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseInmune Bio, Inc. · Alzheimer DiseaseTerminatedINMBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 26, 2023Sponsor estimatePhase 2NCT05321498Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of InflammationInmune Bio, Inc. · Mild Cognitive Impairment (MCI)WithdrawnINMBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2021ActualPhase 1NCT03943264A Biomarker-directed Study of XPro1595 in Patients With Alzheimer'sInmune Bio, Inc. · Alzheimer DiseaseCompletedINMBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner